Bluerocktx
Develops cell therapies for patients with degenerative diseases, including neurology and ophthalmology conditions
Highlights
- New on EvolcAdded 2026-11-08
Recent signals
What changed at Bluerocktx in the last 6 months, newest first. Each line links to its public source.
- 27 Oct 2026 Leadership hire · Hiring Director, Patient Advocacy (Cambridge) bluerocktx.wd5.myworkdayjobs.com
- 25 Sep 2026 Leadership hire · Hiring Senior Director/Vice President, Program Team Leader, Neurology and… (Cambridge) bluerocktx.wd5.myworkdayjobs.com
About Bluerocktx
BlueRock Therapeutics discovers and develops cell therapies intended to replace cells damaged or lost to disease. Its cell+gene platform uses pluripotent stem cells and genetic engineering, with programs in neurology and ophthalmology.
The company is a clinical-stage cell therapy business and a wholly owned, independently operated subsidiary of Bayer AG. Its open roles span research, development, clinical programs, operations, finance and patient advocacy, with locations in Cambridge, Massachusetts, New York City and Toronto.
Product: Cell therapy candidates and a cell+gene platform for developing and manufacturing therapeutic cell types.
Jobs at Bluerocktx
Open roles at Bluerocktx in the Americas (8)
United States 7 · Canada 1. From Bluerocktx's careers page or applicant tracking system; each role links to the employer.
- Director, Translational Medicine, Imaging · Cambridge, United States
- Senior Director, Technical Development Lead, Device · Toronto, Canada
- Associate Director, FP&A · Cambridge, United States
- Senior Director, People Strategy and Engagement · Cambridge, United States
- Associate Director, Translational Medicine and Nonclinical Development · Cambridge, United States
- Senior Director/Vice President, Program Team Leader, Neurology and Pipeline Assets · Cambridge, United States
- Director, Patient Advocacy · Cambridge, United States
- Senior Manager, Accounting · Cambridge, United States
More biotech & pharma companies
BridgeBio Pharma
Develops drugs for rare genetic conditions, including ATTR amyloidosis, achondroplasia and muscular dystrophyGrowingRemote-friendlyBristolmyerssquibb
Biopharmaceutical company developing prescription medicines for serious diseases in oncology, hematology and neuroscienceNew on EvolcCalyx
Clinical trial imaging, RTSM and eClinical services for biopharma sponsors and CROs running preclinical and clinical studiesNew on EvolcRemote-friendlyCorcept Therapeutics
Develops cortisol-modulating medicines for patients with serious diseasesCountable Labs
Single-molecule PCR instruments, assays and testing services for genomics and life-science researchersRemote-friendlyCSBio
Automated peptide synthesizers for labs, pilot plants and GMP manufacturers, from benchtop to 1000 L scaleNew on Evolc
Website technologies
Tools and platforms detected on this company’s website, grouped by purpose. Dates record when Evolc observed them.
Analytics
- Google Tag ManagerMedium confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Integration code on pageinline script loader
Content delivery
- CloudflareHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Response headerserver
- Website resourcedeclared script/iframe or software asset
- Response headerserver
Content management
- WordPressHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Website resourcedeclared script/iframe or software asset
Forms
- Cloudflare TurnstileHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Website resourcedeclared script/iframe or software asset
- Gravity FormsHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Website resourcedeclared script/iframe or software asset
Frontend frameworks
- jQueryHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Website resourcedeclared script/iframe or software asset
Website detection does not establish a paid subscription or company-wide use. Tools loaded after consent or sign-in may be missed. “No longer observed” does not prove the company stopped using a tool.